Saturday, March 1, 2008
Idiopathic pulmonary fibrosis prognosis and treatment
The clinical course of IPF was conducted; After diagnosis, the average survival time of 4 to 6 years. Empirical treatment, usually prednisone dose 1.0mg. Kg-1, Dayton Daily suits, lasted three months. The subsequent three months of gradual reductions to 0.5mg/kg, and lasted three months. Maintenance treatment capacity of 0.25 and lasted for six months each reductions, the need to assess clinical, X-ray and physiological responses. the most common use of second-line drugs for cytotoxic drugs, especially cyclophosphamide or azathioprine, a ~ 100mg daily. response to treatment is different, but the disease early, not obvious before fibrosis more cells to change the period, or corticosteroid treatment of poison cells seems to be improving conditions. if no objective evidence of effective, there was no need for further treatment. Support and palliative treatment, including high concentration oxygen therapy to alleviate hypoxemia; Bacterial infection, given antibiotics. Patients had advanced to the success of lung transplantation.
Subscribe to:
Post Comments (Atom)
3 comments:
What in the world does this mean? I was diagnosed with IPF in August 2006, and continually search the internet for information relative to sustainment of life and new/innovative break-throughs relative to this terrible life sapping disease. This is pure gobblygook and offers absolutely NO prognosis or treatment information whatsoever that any layman or practicing lung specialist can understand. What is the purpose of publishing this "teaser" type of Blog? Who is the intended audience? I need data that deals with the "prognosis and treatment" of IPF, not some diatribe of mixed vowels and syllables that makes absolutely no sense.
Thank you for this comment. I too have IPF and have been relying on Google serch to get me information. But this kind of garbage does not help or give me confidence on the google search. There have been many others that are pulled up and have nothing to do with IPF. Please try better in gettting better inforation
Appreciate the follow-up Dave...would like to share information with you independent of this nonsense...I can be contacted at: spandau@roadrunner.com..if you care to correspond. Am presently in a clinical trial at UCLA...in 3rd year of disease. Hope to hear from you. Jerry
Post a Comment